43 results about "Hypromellose phthalate" patented technology

Provided is a method for producing HPMCP capable of reducing the average particle size of HPMCP particles to an intended range without a pulverization step. Specifically provided is a method for producing hypromellose phthalate, comprising an esterification step of reacting hypromellose with an esterification agent in the presence of a catalyst to obtain a reaction solution containing crude hypromellose phthalate, a precipitation step of mixing the reaction solution with water to precipitate the crude hypromellose phthalate, thereby obtaining a hypromellose phthalate suspension, a liquid removal step of removing a liquid from the hypromellose phthalate suspension with a centrifugal decanter to obtain liquid-removed hypromellose phthalate, and a drying step of drying the liquid-removed hypromellose phthalate.

The invention provides a Febuxostat enteric preparation comprising a medicament inner core, an isolated layer and a casing layer. The Febuxostat enteric preparation adopts hypromellose phthalate ester to wrap an isolated coat and selects cellulose acetate propionate (CAP) and polyvinylacetate phthalate of an enteric-coated material dissolvable in a pH value range of 5-6.8 to wrap an enteric coat.The enteric preparation does not leak after being orally taken into the stomach of a human being, is rapidly dissolved and disintegrated after entering the pylorus with a pH value larger than 5 and releases the Febuxostat medicament for the intestinal tract to rapidly absorb so as to achieve the aim of improving the bioavailability and the healing effect. Compared with a common Febuxostat tablet or capsule, the invention has the advantages of stability in gastric juice, rapid dissolution and absorption in the intestinal tract and high bioavailability, is prepared by general process and is easy to realize the industrialized production.

A solid dispersion and solid dispersion microsphere of paclitaxel or a homologue thereof and a preparation method therefor. By means of preparing a solid dispersion and solid dispersion microsphere to improve the rapid release in vivo and in vitro of paclitaxel or a homologue thereof, and by maintaining a supersaturated drug concentration or, in the case of high molecularity, increasing the apparent solubility of the drug, the bioavailability of the drug is increased. The solid dispersion carrier of paclitaxel or a homologue thereof is either hydroxypropyl methylcellulose acetate succinate or hypromellose phthalate or a mixture thereof or a silica gel-based micropowder mixture. The prepared solid dispersion microsphere has a particle size of between 100 and 600 mum and a yield rate of over 80%; the appropriate drug content therefore is between 5% and 40%.

The invention discloses an ursolic acid solid dispersion and a preparation method thereof. The formula of the ursolic acid solid dispersion comprises ursolic acid and a carrier material; the mass ratio of the ursolic acid to the carrier material is 1:2 to 1:20; and the carrier material is one or more of PEG6000 (polyethylene glycol 6000), povidone k29 / 33, hypromellose E5, polyving alcohol, poloxamer 68, GELUCIRE 50 / 13, polyacrylic resin EPO, polyacrylic resin L 100-55, povidone-vinyl alcohol, hypromellose AS-HG, hypromellose AS-LG, hypromellose AS-MG, low substituted hypromellose, hypromellose phthalate, cellulose acetate phthalate, glucan, polyoxyethylene, polyoxyethylene stearates and polyvinyl acetate phthalate. The preparation method comprises the following steps: dissolving the ursolic acid and the carrier material into an organic solvent according to the formula; removing the organic solvent; and grinding. The ursolic acid solid dispersion has good solubility and has high bioavailability.

The invention provides an enteric complex drug-loaded system with a halloysite nanotube being a skeleton. A preparation method includes the steps that indomethacin is dissolved in acetone, the obtained solution is dropwise added into the halloysite nanotube and stirred evenly, then powder is obtained through vacuum drying and put into a tabletting machine, and tablets are obtained through pressing; hypromellose phthalate, soluble starch, polyvinylpyrrolidone, absolute ethyl alcohol and deionized water are mixed and stirred evenly to obtain a mixed solution; the obtained tablets are coated with the obtained mixed solution, namely a coating solution, cooled to minus 5-0 DEG C in step2 and pulled and taken out after being subjected to complex crosslinking for 3s-2min, coated tablets are obtained, a coating-pulling-freeze drying process is completed once after freeze drying, the process is repeated 1-10 times, and the finished product is obtained. The drug-loaded ratio of the halloysite nanotube for indometacin is greatly increased, slow-release enteric solubility is greatly improved, and the releasing rate of indometacin in artificially simulated gastric fluid is smaller than 20%.

The invention relates to the pharmaceutical field and discloses a cilostazol sustained-release capsule compound and a preparation method thereof. The sustained-release capsule compound comprises a medicinal hollow capsule body and contents arranged in the medicinal hollow capsule body. The contents comprise cilostazol, a hydroxypropyl methylcellulose phthalate sustained-release framework material, a retardant, an adhesive, a filler, an antisticking agent and a lubricating agent. Hydroxypropyl methylcellulose phthalate is used as the framework sustained-release material and is a product obtained by performing an esterification reaction between hydroxypropyl methylcellulose and phthalic anhydride in acetic acid with sodium acetate serving as a catalyst. Molecules have carboxyl negative charge intermolecular repulsion under a carboxyl alkaline environment, so that twinned macromolecules are stretched to be dissolved, and enteric solubility is achieved. The absorption of the cilostazol by the upper gastrointestinal tract can be reduced while the absorption of the cilostazol by the lower gastrointestinal tract is improved. Adverse drug reactions such as headaches, head heaviness and tachycardia caused by sudden increase of the drug concentration are overcome. In addition, the cilostazol sustained-release capsule compound is taken only one time per day, so that the adaptability of patients is improved.

The enteric-coated hollow cellulose capsules disclosed in the present invention are composed in weight percent: hypromellose phthalate: 45-60%, hypromellose: 25-40%, agar: 5.5-10%, chlorinated Potassium: 0.5-1%, Tween-80: 0.5-3%, the balance is water; among them, hypromellose phthalate is Hp55S or Hp55, and hypromellose is HPMC-E4. The preparation method of the enteric-coated hollow cellulose capsule of the present invention does not use any organic solvent, and the general-purpose hollow capsule production line can be used for one-time molding to prepare the enteric-coated hollow cellulose capsule. The surface of the hollow capsule of the present invention is smooth and elastic, and has the stability of not swelling, disintegrating and leaking drugs in the simulated gastric juice environment for 2 hours, and has the characteristics of completely disintegrating and releasing drugs within 1 hour or even 30 minutes in the simulated intestinal juice environment, and The tightness and friability of the product are all qualified, the mechanical properties of the capsule are good, and it has good tolerance to the environment.

The invention relates to a metformin hydrochloride enteric-coated tablet and a preparation method thereof. The metformin hydrochloride enteric-coated tablet includes a tablet core and an enteric coating layer; the tablet core is prepared from the following raw materials in parts by weight: 430-570 parts of metformin hydrochloride, 5-40 parts of binder, 0 parts of disintegrant ~30 parts and 1~10 parts of lubricant; the enteric coating layer is prepared from the following raw materials by weight: 5~40 parts of enteric material, 0.5~30 parts of plasticizer and 1~30 parts of antisticking agent 10 parts; the binder is at least one of hypromellose, hypromellose and povidone; the enteric material is methacrylic acid-ethyl acrylate copolymer, methacrylic acid copolymer , at least one of hypromellose phthalate and polyvinyl acetate phthalate. The metformin hydrochloride enteric-coated tablet of the present invention can release rapidly under the condition of pH 4.5-5, and has good bioequivalence with the original drug.